Results 201 to 210 of about 524,302 (394)

The causal relationship between systemic lupus erythematosus and juvenile myoclonic epilepsy: A Mendelian randomization study and mediation analysis

Ibrain, Volume 11, Issue 1, Page 98-105, Spring 2025.
Mendelian randomization (MR) studies were conducted using the inverse‐variance weighted (IVW) method, MR‐Egger and weighted median on juvenile myoclonic epilepsy (JME), and systemic lupus erythematosus (SLE) data from the Integrative Epidemiology Unit (IEU) Open genome‐wide association study (GWAS) database and the International League Against Epilepsy
Sirui Chen, Ningning Zhang, Ruirui Zhang, Lan Zhang, Dadong Luo, Junqiang Li, Yaqing Liu, Yunan Wang, Xinyue Duan, Xin Tian, Tiancheng Wang   +10 more
wiley   +1 more source

P278 Short and long-term surgical outcomes and pouch function following proctocolectomy and pouch formation in paediatric ulcerative colitis: a multicentre-retrospective cohort study from the Porto IBD working group of ESPGHAN [PDF]

, 2017
E. Orlanski Meyer, Chani Topf‐Olivestone, E. Shtayer, Hagit Tulchinsky, Lars Folmer Hansen, Angelika Kindermann, Amit Assa, Kaija‐Leena Kolho, Sanja Kolaček, Matthew Carroll, Massimo Martinelli, Marina Aloi, Richard Hansen, Harland S. Winter, Víctor Manuel Navas‐López, B Weiß, Neil Shah, Dan Turner   +17 more
openalex   +1 more source

A Dual Action of Everolimus in Ulcerative Colitis: Blocking CLEC4E‐Driven Inflammation and Remodeling the Gut Microbiota‐Metabolite Axis

iMetaMed, EarlyView.
Graphical abstract of the major mechanisms of Everolimus in ulcerative colitis: Everolimus, a selective mTORC1 inhibitor, protects against ulcerative colitis through a dual mechanism. First, Eve directly suppresses CLEC4E/Syk/NF‐κB signaling, thereby reducing pro‐inflammatory cytokine production and preserving intestinal barrier integrity.
Jing Chen, Min Li, Wenyan Sun, Yuyun Chen, Yu Sheng, Cuihua Lu, Zhaoxiu Liu   +6 more
wiley   +1 more source

Epidermal growth factor enemas with oral mesalamine for mild-to-moderate left-sided ulcerative colitis or proctitis [PDF]

, 2003
Berlanga-Acosta, J, Nightingale, JMD, Playford, RJ, Sinha, A, West, KP   +4 more
core   +1 more source

P078 DONOR SELECTION INFLUENCES THERAPEUTIC EFFECTS OF FECAL MICROBIOTA TRANSPLANTATION FOR ULCERATIVE COLITIS [PDF]

, 2020
Keiichi Haga, Dai Ishikawa, Koki Okahara, Kei Nomura, Shoko Ito, Masahito Takahashi, Tomoyoshi Shibuya, Akihito Nagahara   +7 more
openalex   +1 more source

Identification of gene signatures associated with ulcerative colitis and the association with immune infiltrates in colon cancer [PDF]

, 2023
Zhaoji Pan, Hao Lin, Yanyan Fu, Fanpeng Zeng, Feng Gu, Guoping Niu, Jian Fang, Bing Gu   +7 more
openalex   +1 more source

Infliximab for induction and maintenance therapy for ulcerative colitis.

New England Journal of Medicine, 2005
P. Rutgeerts, W. Sandborn, B. Feagan, W. Reinisch, A. Olson, J. Johanns, S. Travers, D. Rachmilewitz, S. Hanauer, G. Lichtenstein, W. D. de Villiers, D. Present, B. Sands, J. Colombel   +13 more
semanticscholar   +1 more source

Weizmannia coagulans XY2 Mitigates Copper Neurotoxicity via Gut–Brain Axis Modulation of Tryptophan Metabolism and Oxidative‐Inflammatory Crosstalk

iMetaOmics, EarlyView.
Copper interferes with tryptophan metabolism and 5‐HT levels by modulating intestinal flora. Intestinal barrier breakdown and inflammatory response trigger nerve damage under copper exposure. W. coagulans XY2 alleviates copper‐induced neurotoxicity by targeting a multi‐dimensional “tryptophan metabolism‐antioxidant defense‐gut‐brain axis” network.
Yufang Gao, Xiaodong Zheng, Fujie Yan
wiley   +1 more source

Monozygotic twins with ulcerative colitis [PDF]

, 1982
J F Mayberry, M. J. Dew, J S Morris
openalex   +1 more source

Efficacy and safety of oral Pentasa (prolonged-release mesalazine) in mild-to-moderate ulcerative colitis: a systematic review and meta-analysis [PDF]

, 2021
Kristine Paridaens, John Fullarton, Simon Travis   +2 more
openalex   +1 more source